State Key Laboratory of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing 100021, China.
Center of Basic Medical Science, Navy General Hospital, Beijing 100048, China.
Sci Rep. 2016 Jun 17;6:28083. doi: 10.1038/srep28083.
Tumor-derived exosomes are important for cell-cell communication. However, the role of TP53 in the control of exosome production in colorectal cancer (CRC) is controversial and unclear. The features of exosomes secreted from HCT116 TP53-wild type (WT), TP53-knockout (KO) and constructed TP53 (R273H)-mutant (MT) cells were assessed. The exosomes from the MT and KO cells exhibited significantly reduced sizes compared with the WT cells. A comprehensive proteomic analysis of exosomal proteins was performed using the isobaric tag for relative and absolute quantitation (iTRAQ)-2D-LC-MS/MS strategy. A total of 3437 protein groups with ≥2 matched peptides were identified. Specifically, hepatocyte growth factor-regulated tyrosine kinase substrate (HGS) was consistently down-regulated in the exosomes from the MT and KO cells. Functional studies demonstrated that low HGS levels were responsible for the decreased exosome size. TP53 regulated HGS expression and thus HGS-dependent exosome formation. Furthermore, the HGS expression was gradually increased concomitant with CRC carcinogenesis and was an independent poor prognostic factor. In conclusion, a novel HGS-dependent TP53 mechanism in exosome formation was identified in CRC. HGS may serve as a novel prognostic biomarker and a candidate target for therapeutic interventions.
肿瘤来源的外泌体在细胞间通讯中起着重要作用。然而,TP53 在结直肠癌(CRC)中外泌体产生的控制中的作用仍存在争议,且并不明确。我们评估了源自 HCT116 TP53 野生型(WT)、TP53 敲除(KO)和构建的 TP53(R273H)-突变(MT)细胞的外泌体的特征。与 WT 细胞相比,MT 和 KO 细胞分泌的外泌体的尺寸明显减小。我们使用等重同位素标记相对和绝对定量(iTRAQ)-2D-LC-MS/MS 策略对外泌体蛋白进行了全面的蛋白质组学分析。共鉴定出 3437 个具有≥2 个匹配肽的蛋白质组。具体而言,在 MT 和 KO 细胞的外泌体中,肝细胞生长因子调节的酪氨酸激酶底物(HGS)一直下调。功能研究表明,低 HGS 水平是外泌体尺寸减小的原因。TP53 调节 HGS 表达,从而调节 HGS 依赖的外泌体形成。此外,HGS 的表达随着 CRC 癌变而逐渐增加,并且是独立的预后不良因素。总之,我们在 CRC 中鉴定出了一种新型的 HGS 依赖的外泌体形成的 TP53 机制。HGS 可作为一种新的预后生物标志物和治疗干预的候选靶点。